Keywords: repligen, usa-based, corp, says, data, preclinical, study

Repligen

Article | 22 September 2008

USA-based Repligen Corp says data from a preclinical study demonstrate that its novel histone deacetylase inhibitor improved disease symptoms in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Nystatin

Go to drug listing